Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment. - Wikidata - awgldk - TriplyDB

Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment.

Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment.

http://www.wikidata.org/entity/Q37970682

about

Immune Evasion Strategies of Glioblastoma Vaccine therapies in malignant glioma Immunotherapy advances for glioblastoma An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma Clinical efficacy of tumor antigen-pulsed DC treatment for high-grade glioma patients: evidence from a meta-analysis Prospects of immune checkpoint modulators in the treatment of glioblastoma Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patients An integrative characterization of recurrent molecular aberrations in glioblastoma genomes.PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment Cytokine responsiveness of CD8(+) T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients.Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model.Ipilimumab augments antitumor activity of bispecific antibody-armed T cells Current status of gene therapy for brain tumors.Differential glioma-associated tumor antigen expression profiles of human glioma cells grown in hypoxia.Targeted therapy of glioblastoma stem-like cells and tumor non-stem cells using cetuximab-conjugated iron-oxide nanoparticles FGL2 as a Multimodality Regulator of Tumor-Mediated Immune Suppression and Therapeutic Target in Gliomas Dendritic cell immunotherapy versus bevacizumab plus irinotecan in recurrent malignant glioma patients: a survival gain analysis.Combinatorial strategies for oncolytic herpes simplex virus therapy of brain tumors.Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma.Immunotherapy in glioblastoma: emerging options in precision medicine Recent advances and future of immunotherapy for glioblastoma.Effects of salidroside on glioma formation and growth inhibition together with improvement of tumor microenvironment Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas.Convection enhanced delivery of panobinostat (LBH589)-loaded pluronic nano-micelles prolongs survival in the F98 rat glioma model.Advances in Immunotherapy for Glioblastoma Multiforme.The spectrum of vaccine therapies for patients with glioblastoma multiforme Vaccine strategies for glioblastoma: progress and future directions.Current and future directions for Phase II trials in high-grade glioma.The role of targeted therapies in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.Current trends in glioblastoma multiforme treatment: radiation therapy and immune checkpoint inhibitors Vaccine therapies for patients with glioblastoma.Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme.Current Studies of Immunotherapy on Glioblastoma Cancer nanoimmunotherapy using advanced pharmaceutical nanotechnology.Glioblastoma stem cells and stem cell-targeting immunotherapies.Combining immunotherapy with radiation for the treatment of glioblastoma.Glioblastoma antigen discovery--foundations for immunotherapy.Spatially gradated hydrogel platform as a 3D engineered tumor microenvironment.Enhanced immunosuppression by therapy-exposed glioblastoma multiforme tumor cells.NKG2D ligand expression in pediatric brain tumors.

P2860

Q26765855-92B18DFA-618A-4A8F-972A-4A8CF8A6FAEE Q26829328-72034B30-0214-4B11-9EF3-DB3268128660 Q26866513-B448C09C-412D-4D8E-A46C-0F089C94F573 Q27024830-03BBF164-7739-42E6-ACCC-946681E4A74C Q27348437-BB539952-82B3-4335-8B08-746A1DFC909F Q28081371-CB899CA1-B5B7-499D-B340-0E8EFC767733 Q28730798-6A9E5823-70F3-4E3F-8EBC-0874D84ACE0A Q30551524-D6727C28-CBBD-4BF0-9778-679385EF77AD Q33275412-E9B83B08-4FD6-41B3-9BA2-92F31D9E7118 Q33691858-DD9F1CF5-DC3D-4CE4-BCB7-3450B6C4D3C9 Q33889603-FF9E1332-AF76-458B-87B7-6662D7883E2E Q33929184-79836D2A-8A14-4F90-B620-1A5D37864908 Q34318157-481EC524-80C8-4FE9-8119-BF520AABA2DB Q34407938-C99D1D0B-D908-4A50-B1B9-C0E0591E3B7F Q35832224-F41F39E0-EE6C-4148-8717-4C0A8E737A6C Q36009621-8B359992-5632-469B-ACB8-9F6838B088BF Q36201736-C9B8A713-3B54-42A7-A517-CAB327BBB7F3 Q36849213-48EAC987-C5FB-4B39-A3C9-CB03C25727AE Q36907372-2E1F2030-C47E-4AEC-826E-FB231E32D5FD Q37050960-F24306CC-5D61-400C-BA94-62AB7C063F99 Q37239071-415EEAF6-E4DA-4BC7-A132-6155CEE8048B Q37309461-8CB2ABF3-2986-4AF0-A049-92472BB3BAA9 Q37435455-ECEDF959-1C91-4929-BBE6-216642A2A5C3 Q37669168-FB4B47A9-8316-41A1-8872-1B5C5A0E400A Q37680966-9F8EDD7C-5D3D-47FE-AD9B-B0921F81463E Q38035788-39592478-EDDF-4EA2-933A-0D33CE0D0E5E Q38081910-B54185AB-2B6A-42CB-A258-71D8C1B1DA53 Q38094808-825BDB30-3929-456E-8A47-7F211BC6BC8C Q38205134-D9094574-2041-4349-8AEF-FF20A062495C Q38218134-10D23034-2D09-4096-B062-255BB53D628B Q38243975-D2E7EA2F-D638-4D54-ACB0-DCD82D55CC4D Q38245925-35CABE55-2D30-4A7B-B12C-928EEBD9EA21 Q38262914-5EA33D67-9171-4D07-9775-27ADD1A9B15C Q38285751-7C6E778C-3E9F-4357-AC44-AE1A2FF6E13D Q38355702-4482FAB3-A5DE-49BE-9709-4AF339840028 Q38422623-BE395CD8-02F8-497D-BFC2-269DC1768AC2 Q38516823-F3F0C752-F9E9-4077-AC3F-DC690A880337 Q38927445-406AA619-9224-4B18-BC43-6444AB9B8F2F Q38943301-02FEBB22-4E7A-4960-B244-4A6C770F7239 Q39196323-E2348D17-1AF3-448F-8949-31AE510A7C3C

P2860

Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment.

http://www.wikidata.org/entity/Q37970682

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment.

@en

Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment.

@nl

type

label

Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment.

@en

Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment.

@nl

prefLabel

Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment.

@en

Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment.

@nl

P1433

Q37970682-24FD40C7-79B0-4AD7-AB57-1B2B666E1850

P1476

Q37970682-0EB7FD53-D8FE-41EF-BFC3-2C31320EE04B

P2093

Q37970682-340B4FAF-EA11-4E71-9532-EDAE44C26AF4

Q37970682-4853E133-D24E-4309-B82D-0804F7CEA2CA

Q37970682-4F4B47A0-CE9B-4817-AACE-A3CA7CBEA746

Q37970682-751D0528-0BE8-452E-8401-F11C86C7A4DF

Q37970682-900658F4-0EC6-4470-B99D-D5D95BB2E15F

P275

Q37970682-64A64C0B-565A-4C07-B03F-24F41B23B8B1

P2860

Q37970682-0069D82E-644F-485D-8CAC-A9A0F05EE408

Q37970682-00FC444C-1AB3-4166-B2FF-997354F0E13A

Q37970682-0233301F-9D92-4C47-A9B6-80A86310AD43

Q37970682-04C6F67C-7F0F-4107-8344-5A3CBC7D9692

Q37970682-050EB2ED-1AF2-45C1-BCCF-424354F3036D

Q37970682-0558291A-56C1-4C1E-BEDF-C2CBE1E57EDB

Q37970682-05C014EF-8005-4CBE-B28D-06DC782CE76E

Q37970682-06D962D1-9BF0-4408-89D6-A0B723C02ABC

Q37970682-0723BE32-0BD9-470B-88CB-3692BC79A98E

Q37970682-090A3E54-AAA8-4E0F-8C7C-70FCD491C660

P304

Q37970682-52CEE428-7998-4001-890B-F7DB0CC430D3

P31

Q37970682-1C502F91-8F05-4FAD-BCD4-32AE6967A96A

Q37970682-F16A8904-CB3F-4245-BA29-432D2FB062CF

P356

Q37970682-9C50E1BC-6EA4-4A3A-85D1-C1D2E06A03DA

P478

Q37970682-4241A24A-55E4-40C6-8E03-4DD985D5B728

P5008

Q37970682-9724BC36-7532-42CC-8BEF-0A677793803A

P577

Q37970682-821DBD56-4F3B-4927-8B3A-F2154F7323A2

P5875

Q37970682-043560D9-AC00-4126-9771-ECDA6C11F09E

P698

Q37970682-5AB79E71-5069-488D-AB3E-DCBFD565CCE3

P921

Q37970682-2B28E74D-B74C-4F4A-AE56-578BEC204B81

Q37970682-5674C5B0-2A0F-474B-A11C-2F332B65B3FF

P932

Q37970682-26F27AA9-E1E2-4F4A-A4DA-7848DFF69D6D

P356

P1433

Clinical and Developmental Immunology

P1476

Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment.

@en

P2093

Christopher Jackson

http://www.w3.org/2001/XMLSchema#string

Jacob Ruzevick

http://www.w3.org/2001/XMLSchema#string

Jillian Phallen

http://www.w3.org/2001/XMLSchema#string

Michael Lim

http://www.w3.org/2001/XMLSchema#string

Zineb Belcaid

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 3.0 Unported

P2860

Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-beta gene family

Cancer immunotherapy: moving beyond current vaccines

Noninvasive detection of therapeutic cytolytic T cells with 18F-FHBG PET in a patient with glioma

Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation

Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Glycosylation-induced conformational modification positively regulates receptor-receptor association: a study with an aberrant epidermal growth factor receptor (EGFRvIII/DeltaEGFR) expressed in cancer cells.

Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain

P304

732413

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2011/732413

http://www.w3.org/2001/XMLSchema#string

P478

2011

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2011-12-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51905205

http://www.w3.org/2001/XMLSchema#string

P698

22190972

http://www.w3.org/2001/XMLSchema#string

P921

P932

3235820

http://www.w3.org/2001/XMLSchema#string